OncoCyte Corporation Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.67 | -$0.67 | -$0.67 |
| Q2 2024 | 1 | -$0.56 | -$0.56 | -$0.56 |
| Q3 2024 | 1 | -$0.44 | -$0.44 | -$0.44 |
| Q4 2024 | 1 | -$0.45 | -$0.45 | -$0.45 |
| Q1 2025 | 2 | -$0.48 | -$0.42 | -$0.45 |
| Q2 2025 | 1 | -$0.46 | -$0.46 | -$0.46 |
| Q3 2025 | 1 | -$0.43 | -$0.43 | -$0.43 |
| Q4 2025 | 1 | -$0.42 | -$0.42 | -$0.42 |
| Q1 2026 | 1 | -$0.39 | -$0.39 | -$0.39 |
| Q2 2026 | 1 | -$0.36 | -$0.36 | -$0.36 |
| Q3 2026 | 1 | -$0.34 | -$0.34 | -$0.34 |
| Q4 2026 | 1 | -$0.33 | -$0.33 | -$0.33 |
OncoCyte Corporation Earnings Date And Information
OncoCyte Corporation last posted its earnings results on Thursday, August 8th, 2024. The company reported $-0.36 earnings per share for the quarter, topping analysts' consensus estimates of $-0.56 by $0.2. The company had revenue of 115,000 for the quarter and had revenue of 1.50 M for the year. OncoCyte Corporation has generated $-4 earnings per share over the last year ($-3.75 diluted earnings per share) and currently has a price-to-earnings ratio of -0.84. OncoCyte Corporation has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based on prior year's report dates.
OncoCyte Corporation Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/12/2024 | Q3 2024 | -$0.98 | $178,333 | $115,000 | ||
| 08/08/2024 | Q2 2024 | -$0.56 | -$0.36 | 0.2 | $318,550 | $104,000 |
| 05/15/2024 | Q1 2024 | -$0.67 | -$1.10 | -0.43 | $176,000 | |
| 04/15/2024 | Q4 2023 | -$1.94 | $314,000 | |||
| 11/09/2023 | Q3 2023 | -$1.52 | -$0.79 | 0.73 | $312,500 | $429,000 |
| 08/10/2023 | Q2 2023 | -$2.60 | -$20.60 | -18 | $362,500 | $463,000 |
| 05/12/2023 | Q1 2023 | $0.40 | $297,000 | |||
| 04/12/2023 | Q4 2022 | -$7.64 | $-3,550,000 | |||
| 11/10/2022 | Q3 2022 | -$2.60 | -$1.59 | 1.01 | $2.71 M | $1.02 M |
| 08/11/2022 | Q2 2022 | -$1.42 | $2.24 M | $2.07 M | ||
| 05/12/2022 | Q1 2022 | -$2.32 | $1.42 M | |||
| 05/02/2022 | Q4 2021 | -$7.88 | $3.59 M | |||
| 11/09/2021 | Q3 2021 | -$1.40 | -$3.02 | -1.62 | $1.57 M | $984,000 |
| 08/11/2021 | Q2 2021 | -$2.34 | $838,017 | $2.03 M | ||
| 05/17/2021 | Q1 2021 | -$1.80 | -$0.95 | 0.85 | $1.12 M | |
| 03/19/2021 | Q4 2020 | -$1.87 | $503,000 | |||
| 11/12/2020 | Q3 2020 | -$1.80 | -$2.02 | -0.22 | $47,200 | $555,000 |
| 07/29/2020 | Q2 2020 | -$2.20 | -$2.77 | -0.57 | $143,000 | |
| 05/12/2020 | Q1 2020 | -$2.20 | -$2.52 | -0.32 | $16,000 | |
| 04/28/2020 | Q4 2019 | -$2.92 | $0 |
OncoCyte Corporation Earnings: Frequently Asked Questions
-
When is OncoCyte Corporation's earnings date?
OncoCyte Corporation has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off last year's report dates.
-
Did OncoCyte Corporation beat their earnings estimates last quarter?
In the previous quarter, OncoCyte Corporation (:OCX) reported $-0.36 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.56 by $0.2.
-
How can I listen to OncoCyte Corporation's earnings conference call?
The conference call for OncoCyte Corporation's latest earnings report can be listened to online.
-
How can I read OncoCyte Corporation's conference call transcript?
The conference call transcript for OncoCyte Corporation's latest earnings report can be read online.
-
How much revenue does OncoCyte Corporation generate each year?
OncoCyte Corporation (:OCX) has a recorded annual revenue of $1.50 M.
-
How much profit does OncoCyte Corporation generate each year?
OncoCyte Corporation (:OCX) has a recorded net income of $1.50 M. OncoCyte Corporation has generated $-3.75 earnings per share over the last four quarters.
-
What is OncoCyte Corporation's price-to-earnings ratio?
OncoCyte Corporation (:OCX) has a price-to-earnings ratio of -0.84 and price/earnings-to-growth ratio is 0.17.
